The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment
Status:
Unknown status
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Recent studies have described the role of melatonin as a sleep regulator and as an anti-
oxidative neuroprotective agent in improving sleep quality and delaying cognitive decline in
Alzheimer's disease (AD).
In accordance with this data, our hypothesis is that melatonin will delay the cognitive
decline in Mild Cognitive Impairment (MCI) patients and reduce the conversion rate from MCI
to AD.